Cited by 1,171Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsPharmacology and Obesity Treatment

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis

Open access
Gillies, Clare L, Abrams, Keith R, Lambert, Paul C, Cooper, Nicola J, Sutton, Alex J, Hsu, Ron T, Khunti, Kamlesh·2007·BMJ

Abstract

OBJECTIVE: To quantify the effectiveness of pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance. DATA SOURCES: Medline, Embase, and the Cochrane library searched up to July 2006. Expert opinions sought and reference lists of identified studies and any relevant published reviews checked. STUDY SELECTION: Randomised controlled trials that evaluated interventions to delay or prevent type 2 diabetes in individuals with impaired glucose tolerance. RESULTS: 21 trials met the inclusion criteria, of which 17, with 8084 participants with impaired glucose tolerance, reported results in enough detail for inclusion in the meta-analyses. From the meta-analyses the pooled hazard ratios were 0.51 (95% confidence interval 0.44 to 0.60) for lifestyle interventions v standard advice, 0.70 (0.62 to 0.79) for oral diabetes drugs v control, 0.44 (0.28 to 0.69) for orlistat v control, and 0.32 (0.03 to 3.07) for the herbal remedy jiangtang bushen recipe v standard diabetes advice. These correspond to numbers needed to treat for benefit (NNTB) and harm (NNTH) of 6.4 for lifestyle (95% credible interval, NNTB 5.0 to NNTB 8.4), 10.8 for oral diabetes drugs (NNTB 8.1 to NNTB 15.0), 5.4 for orlistat (NNTB 4.1 to NNTB 7.6), and 4.0 for jiangtang bushen (NNTH 16.9 to NNTB 24.8). CONCLUSIONS: Lifestyle and pharmacological interventions reduce the rate of progression to type 2 diabetes in people with impaired glucose tolerance. Lifestyle interventions seem to be at least as effective as drug treatment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.39063.689375.55

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The DPPOS finding that lifestyle and metformin delayed or prevented diabetes agrees with other reports of similar lifestyle or antidiabetic drug interventions.

    “Our findings that both lifestyle and metformin interventions delayed or prevented diabetes in the DPPOS are consistent with results of other reports of similar interventions with lifestyle or with other antidiabetic drugs.24,25”
  • Sixteen of the systematic reviews included exclusively people with intermediate hyperglycaemia.

    “Sixteen of these systematic reviews included exclusively people with intermediate hyperglycaemia (Aguiar 2014; Gillett 2012; Gillies 2007; Glechner 2015; Gong 2015; Hopper 2011; ICER 2016; Norris 2005; Santaguida 2005; Selph 2015; Stevens 2015; Yamaoka 2005; Yates 2007; Yoon 2013; Yuen 2010; Zheng 2016);”
  • Lifestyle and pharmacological interventions reduced the rate of progression to type 2 diabetes in people with impaired glucose tolerance, and these interventions seem as effective as pharmacological treatment.

    “In their systematic review, Gillies et al. found that lifestyle and pharmacological interventions reduced the rate of progression to type 2 diabetes in people with IGT and that these interventions seem to be as effective as pharmacological treatment.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 43 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. [4]4. Angelo JB, Huang J, Carden D. Diabetes prevention: a review of current literature. Adv Stud Med 2005;5:250-9.
  2. [16]16. Sharp SJ, Thompson SG. Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. Stat Med 2000;19:3251-74.
  3. [19]19. World Health Organization Expert Committee. Diabetes mellitus, second report. World Health Organ Tech Rep Ser 1980;646:1-80.
  4. [20]20. WHO Study Group. Diabetes mellitus. World Health Organ Tech Rep Ser 1985;727:1-113.

Cited by

Sorted by citations

Authors
Gillies, C. L., Abrams, K. R., Lambert, P. C., Cooper, N. J., Sutton, A. J., Hsu, R. T., & Khunti, K.
Affiliations
University of Leicester (GB)
Corresponding author
Gillies, Clare L
Venue
BMJ
Publisher
BMJ
Published
2007-01-19
Volume
334
Issue
7588
Pages
299
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
OpenAlex
W2096691922
Cited by
1,171
References
43
Citations by year
2026: 12 · 2025: 19 · 2024: 38 · 2023: 38 · 2022: 40 · 2021: 47 · 2020: 56 · 2019: 56 · 2018: 51 · 2017: 78 · 2016: 74 · 2015: 75 · 2014: 98 · 2013: 97 · 2012: 100
FWCI
9.97
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Leicester Research Archive (University of Leicester) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Medical Research Council
  • Economic and Social Research Council
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
type 2 diabetes prevention, impaired glucose tolerance, lifestyle intervention, pharmacological interventions, oral antidiabetic drugs, orlistat, diabetes progression, number needed to treat
MeSH terms
Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Life Style, Randomized Controlled Trials as Topic, Treatment Outcome, Publication Bias, Glucose Intolerance

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review